Please login to the form below

Not currently logged in
Email:
Password:

Symphogen

This page shows the latest Symphogen news and features for those working in and with pharma, biotech and healthcare.

Baxalta makes $1.7bn play for slice of CAR-T market

Baxalta makes $1.7bn play for slice of CAR-T market

The deal comes a few weeks after Baxalta agreed a deal with Symphogen worth up to $1.6bn to develop a series of novel checkpoint inhibitor drugs, making a bold foray

Latest news

  • Baxalta agrees to $32bn Shire takeover Baxalta agrees to $32bn Shire takeover

    Meanwhile, eyebrows were raised earlier this month when Baxalta signed a $1.6bn deal with Symphogen in oncology - which is not a major focus of either of the merging companies although

  • Baxalta inks $1.6bn immuno-oncology deal with Symphogen Baxalta inks $1.6bn immuno-oncology deal with Symphogen

    Baxalta is paying $175m upfront for an option on a series of six checkpoint inhibitors in early-stage development at privately-held Danish biopharma Symphogen, along with milestone payments worth up ... Copenhagen-based Symphogen said the first of the

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    Only days before this, Baxalta had announced the investment of $175m upfront in a strategic collaboration with Symphogen taking the company into the ever popular field of oncology (headline deal value ... upfront. 1, 900. Symphogen/ Baxalta.

  • Pharma deals during September 2012 Pharma deals during September 2012

    In its search for a follow-on to Erbitux, Merck KGaA has taken an exclusive worldwide licence to Symphogen's Sym004, currently in phase I/II trials, for the treatment of ... 665. Symphogen / Merck KGaA. Product licence. Sym004 for advanced KRAS; a

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics